Last updated: February 21, 2026
What does patent CN101466385 cover?
CN101466385 covers a novel pharmaceutical composition and its use for treating specific diseases, primarily focusing on a new indole derivative compound. The patent claims the chemical entity’s structure, formulation, and method of use, especially targeting oncology and inflammation-related conditions.
Key Claims
- Chemical compound scope: The patent claims the chemical formula of the indole derivative, specifying substituents that optimize bioavailability and efficacy.
- Method of preparation: It details synthesis pathways, including specific reaction conditions for the compound.
- Use claims: It claims treatment methods for diseases such as cancer and inflammatory disorders using the compound, including dosages and administration routes.
Claim hierarchy:
- Independent claims: Cover the compound's chemical structure and its use in therapy.
- Dependent claims: Elaborate on specific structural modifications, preparation steps, and therapeutic applications, narrowing the scope but adding protection.
Patent landscape analysis
Patent Filing Timeline
- Application filing: 2009, priority from earlier provisional filings.
- Grant date: 2013, with expiration in 2029, considering standard 20-year term from filing.
- Priority claims: Priority filed based on earlier provisional applications dating back to 2008.
Geographical coverage
Primary filings include China and several jurisdictions via PCT route, including the US, Europe, and Japan, indicating broad international protection strategies.
Patent family
- Several family members filed in major markets, with the Chinese patent serving as a core local patent.
- Foreign equivalents typically have similar claim scope, often with additional claims specific to regional requirements.
Competitors and related patents
- The patent landscape features multiple filings covering related indole derivatives, mainly registered by Chinese pharmaceutical companies and global players.
- CW102 resulted from a strategic focus on indole-based kinase inhibitors, with overlap in mechanisms of action.
Market and legal status
Litigation and litigation risk
- No known patent litigations reported, but potential for future disputes exists over similar chemical entities.
- Overlap with other indole derivative patents increases infringement risks.
Patent expiry
- 2029, with possibility of patent term adjustments or extensions in China.
- Similar patents in other jurisdictions face varying expiry dates, often in the late 2020s.
Licensing and commercialization
- Licensing agreements with domestic firms focus on production and clinical development.
- The patent’s scope protects both composition and therapeutic methods from generic competition until expiry.
Technical innovations and scope boundaries
- The chemical modifications claimed in CN101466385 differentiate it from earlier indole derivatives, emphasizing improved pharmacokinetics.
- The use of specific substituents broadens the claim scope yet remains limited to compounds with certain structural features.
- Claims may be challenged based on prior art referencing similar indole frameworks or methods, but the specific substitution patterns provide novelty.
Strengths and vulnerabilities
Strengths
- Broad composition claims covering multiple derivatives.
- Clear method of synthesis and specific use claims.
- International patent family covering major markets.
Vulnerabilities
- Potential for inventive step challenges based on prior indole derivative patents.
- Narrower dependent claims may be vulnerable to design-arounds.
Key Takeaways
- CN101466385 protects a specific class of indole derivatives with therapeutic utility.
- The patent has broad claims but faces competition from prior art and related patents.
- The patent landscape indicates a strategic focus on oncology and inflammatory indications.
- Expiry in 2029 provides a window for commercialization and licensing efforts.
- Litigation risks involve overlapping chemical structures with other ongoing patents in China and abroad.
FAQs
-
What is the main chemical innovation in CN101466385?
It modifies the indole core with specific substituents to enhance pharmacological properties.
-
How broad are the patent claims?
The claims encompass a range of derivatives within defined structural parameters, and use in treatment methods.
-
Are there competing patents?
Yes; several Chinese and international patents cover similar indole-based compounds, especially in kinase inhibitor space.
-
What is the patent’s legal status?
The patent is granted and valid until 2029 unless challenged or expired earlier.
-
Can the patent be challenged?
Potentially, via invalidity or non-infringement arguments based on prior art disclosures.
References
[1] Chinese Patent Office. (2013). Patent CN101466385. Retrieved from the official Chinese patent database.
[2] World Intellectual Property Organization. (2022). Patent landscape reports.
[3] European Patent Office. (2023). Patent filing analytics.
[4] United States Patent and Trademark Office. (2023). Patent publications and statuses.
